Subject(s)
Aniline Compounds/therapeutic use , Bone Marrow Neoplasms/drug therapy , Bone Marrow Neoplasms/secondary , Leukemia, Myeloid, Acute/drug therapy , Oligopeptides/therapeutic use , Prostatic Neoplasms/pathology , Pyrazines/therapeutic use , Bone Marrow Neoplasms/genetics , Bone Marrow Neoplasms/pathology , Gonadotropin-Releasing Hormone/agonists , Humans , Leukemia, Myeloid, Acute/genetics , Male , Middle Aged , Mutation/drug effects , Prostatic Neoplasms/drug therapy , Prostatic Neoplasms/genetics , fms-Like Tyrosine Kinase 3/geneticsABSTRACT
The novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is rapidly spreading across the world. We encountered two patients with COVID-19 who underwent treatment for acute leukemia at initial diagnosis. Both the patients received conventional induction therapy without the exacerbation of COVID-19. Although the impact of SARS-CoV-2 on the treatment of leukemia is unclear, our treatment experience suggests that there is no major contraindication to standard chemotherapy for acute leukemia in patients with COVID-19. As COVID-19 continues to be a threat worldwide, further evaluations of large cohorts are needed for future treatment decisions for acute leukemia with COVID-19.
Subject(s)
COVID-19 , Leukemia , Humans , Polymerase Chain Reaction , SARS-CoV-2ABSTRACT
This is the first report of a case of COVID-19 after allogeneic stem cell transplantation. Our case suggests that COVID-19 may exist without characteristic CT images, especially in immunocompromised hosts, such as patients after transplantation.